Incidence and risk factors for immune effector cell-associated neurotoxicity syndrome in older patients with relapsed or refractory large B-cell lymphoma: A multicenter study
Multicenter analysis reveals high cumulative incidence of neurotoxicity in older patients with large B-cell lymphoma, suggesting targeted assessments are needed.
Key Points
Cumulative incidence of all grade neurotoxicity was 50.9% in older patients with relapsed B-cell lymphoma, indicating a significant concern for treatment.
Progression-free survival was analyzed using the Kaplan-Meier method, revealing a median of 10.5 months for patients undergoing therapy.
Patients with autologous stem cell transplant exhibited notable variations in clinical outcomes, emphasizing individual risk factors in treatment plans.
Management strategies included various therapies indicating the need for tailored approaches based on clinical profiles and neurotoxicity severity.